Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and r

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the

GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer tra

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescr

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $6

The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing custome

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Z

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter en

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst c

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “Goo

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Compan

GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected

Investors interested in Medical Services stocks are likely familiar with GoodRx Holdings, Inc. (GDRX

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched [ur

New service brings together free and low-cost generic medications, affordable online care visits, an

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription

You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans.

GoodRx Holdings, Inc. faces ongoing revenue and margin pressure as its legacy business declines and

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises

Cramer recommends buying Chevron (CVX) due to good cash flow and limited downside, and waiting to bu

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook,

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter en

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $750.000 million-$780.000 million to

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.07 per share which met the analyst c

GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced tha

GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed techn

Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support throu

GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of M

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced th

Collaboration expands access to trusted therapies with discounted cash prices for leading brands inc

Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight an

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers

Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lo

Mizuho analyst Steven Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lower

Sentiment Change Creates Opportunity